Observational studyAmerican journal of clinical dermatology2026

Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System.

Megan Lau et al.PubMed ↗Publisher ↗

No numbers read from the abstract.